Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Stefanov Ventzislav	2. Date of Event Requiring Statement (MM/DD/YYYY) 9/18/2020	3. Issuer Name and Ticker or Trading Symbol Summit Therapeutics Inc. [SMMT]
(Last)        (First)        (Middle) C/O SUMMIT THERAPEUTICS INC.,, ONE BROADWAY, 14TH FLOOR	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                          _____ 10% Owner ___X___ Officer (give title below)        _____ Other (specify below) See Remarks /
(Street) CAMBRIDGE, MA 02142       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	14900 (1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(2)	12/23/2029	Common Stock	200000	$1.37	D
Stock Option (right to buy)	(3)	5/1/2030	Common Stock	1000000	$3.30	D
Stock Option (right to buy)	(4)	5/1/2030	Common Stock	27273	$3.30	D
Stock Option (right to buy)	(5)	7/8/2030	Common Stock	200000	$3.31	D

Explanation of Responses:
(1)	Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Summit Therapeutics Inc., a Delaware corporation ("New Summit") to the attributes of Summit Therapeutics plc, a public limited company incorporated in England and Wales ("Old Summit"), the predecessor issuer. The succession occurred following the effectiveness, on September 18, 2020, of a United Kingdom court-approved scheme of arrangement in which every five ordinary shares, 0.01 pound sterling par value per share, of Old Summit were exchanged for one share of common stock, $0.01 par value per share, of New Summit, which resulted in New Summit becoming the holding company of Old Summit and its subsidiaries.
(2)	The option was granted on December 23, 2019. The shares underlying the option are scheduled to vest in four equal annual installments with the first installment occurring on the one year anniversary of the grant date, or sooner on the happening of certain corporate events reflecting the achievement of the company's long-term objectives.
(3)	The option was granted on May 1, 2020. The shares underlying the option are scheduled to vest quarterly over a four year period subject to the satisfaction of certain performance targets.
(4)	The option was granted on May 1, 2020. The shares underlying the option are scheduled to vest in full on May 1, 2021.
(5)	The option was granted on July 8, 2020. The shares underlying the option are scheduled to vest in four equal annual installments with the first installment occurring on the one year anniversary of the grant date subject to the satisfaction of certain performance targets.

Remarks: Executive Vice President and President of Discuva Exhibit List: Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Stefanov Ventzislav C/O SUMMIT THERAPEUTICS INC., ONE BROADWAY, 14TH FLOOR CAMBRIDGE, MA 02142	X		See Remarks

Signatures
/s/ Michael Paul Donaldson, Attorney-in-Fact		9/18/2020
**Signature of Reporting Person		Date